Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Gross Margin · Q3 FY2026 · quarter ended Sep 2026
Gross margin narrows to -232.1%
Gross margin was -232.1% in Q3 FY2026, down 311.3 pp from a year earlier. On a trailing-twelve-month basis it was 0.5%, down 88.3 pp year over year. Over 3 fiscal years it narrowed by 3.1 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 93.2%
- Year-over-year change
- +0.2pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.2% | +0.2pp |
| FY2024 | 2024-12-31 | 93.0% | +2.1pp |
| FY2023 | 2023-12-31 | 90.9% | -5.4pp |
| FY2022 | 2022-12-31 | 96.3% | -0.1pp |
| FY2021 | 2021-12-31 | 96.4% | — |
Gross Margin vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 gross margin of 0.5% is the lowest of the 5 companies compared; the peer median is 90.3%.
- Its year-over-year change of -88.3 pp is the lowest of 5, against a peer median of +9.9 pp.
- Over three fiscal years its change of -3.1 pp compares with a peer median of +7.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 100.0% | +20.1 pp | +326.6 pp | |
| LTM Jun 2026 | 91.1% | +2.0 pp | +10.7 pp | |
| LTM Mar 2026 | 89.5% | +17.7 pp | -1.6 pp | |
| LTM Mar 2026 | 74.1% | -0.4 pp | +3.7 pp | |
| LTM Sep 2026 | 0.5% | -88.3 pp | -3.1 pp | |
TTRXTurn Therapeutics Inc. | FY2025 | — | — | — |
| Peer median (excluding TARS) | 90.3% | +9.9 pp | +7.2 pp | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Cost of Revenue | 2.08M | 955K | 1.59M | 12.83M | 30.68M |
| Gross Profit | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Gross Margin | 96.4% | 96.3% | 90.9% | 93.0% | 93.2% |
| Research & Development | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Selling, General & Admin | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M |
| Operating Expenses | 67.11M | 87.57M | 159.01M | 290.7M | 491.65M |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| EBITDA | (13.46M) | (59.71M) | (131.67M) | (106.48M) | (53.61M) |
| EBITDA Margin | -23.6% | -231.3% | -754.7% | -58.2% | -11.9% |
| Operating Income | (12.16M) | (62.71M) | (143.16M) | (120.57M) | (70.97M) |
| Operating Margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest Income | 36K | 3.5M | 10.34M | 15.01M | 15.75M |
| Interest Expense | 0 | 2.06M | 3.23M | 7.45M | 8.94M |
| Other Income / Expenses | (1.62M) | 617K | 7.27M | 5.02M | 6.61M |
| Income Before Tax | (13.77M) | (62.1M) | (135.89M) | (115.55M) | (64.36M) |
| Pre-Tax Margin | -24.1% | -240.5% | -778.9% | -63.2% | -14.3% |
| Income Tax Expense | 55K | (4K) | 0 | 0 | 2.06M |
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Net Margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (Basic) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| EPS (Diluted) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| Weighted Avg Shares | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
| Weighted Avg Shares (Diluted) | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.